{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:27:18Z","timestamp":1790836038041,"version":"4.1.0"},"reference-count":36,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In the past decade, nine antibody-drug conjugates (ADCs) have been approved for the treatment of various tumors, four of which specifically for solid malignancies. ADCs deliver the cytotoxic payload to the cancer site, thereby improving chemotherapy efficacy while reducing systemic drug exposure and toxicity. With their high selectivity, ADCs are associated with a manageable side-effect profile, with nausea and vomiting being among the most frequent toxicities, although this may vary according to the respective ADC and the associated payload. Information about the emetic risk of the new ADC compounds is limited. Three virtual focus groups of Italian oncologists were held to raise awareness on the importance of an antiemetic prophylaxis regimen to prevent and mitigate ADC-associated emesis and its sequelae. After reviewing published evidence and guidelines, the three expert panels shared their experience on the early use of ADCs gained through the participation in specific clinical trials and their clinical practice. The following issues were discussed: antiemetic therapy during trastuzumab deruxtecan treatment, with a protocol adopted at the San Raffaele Hospital (Milan, Italy); the use of steroids; the management of anticipatory nausea during trastuzumab deruxtecan therapy; nutritional counselling; and effective doctor\u2013patient communication. The experts acknowledged that recommendations should be drug-specific, and formulated opinion-based advice intended to guide physicians in their daily practice until further evidence emerges.<\/jats:p>","DOI":"10.3390\/cancers14041022","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T20:24:26Z","timestamp":1645129466000},"page":"1022","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-6267","authenticated-orcid":false,"given":"Giampaolo","family":"Bianchini","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, IRCCS Ospedale San Raffaele, 20132 Milan, Italy"},{"name":"School of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-8658","authenticated-orcid":false,"given":"Laura","family":"Biganzoli","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Department of Oncology, Hospital Santo Stefano, 59100 Prato, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[{"name":"Oncology Unit 3, Department of Oncology, Veneto Institute of Oncology IRCCS, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4938","authenticated-orcid":false,"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[{"name":"Department of Medicine (DAME), University of Udine, 33100 Udine, Italy"},{"name":"Department of Medical Oncology, Unit of Medical Oncology and Cancer Prevention, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Campus Bio-Medico, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, 16132 Genova, Italy"},{"name":"Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8247-9224","authenticated-orcid":false,"given":"Giovanni","family":"Pappagallo","sequence":"additional","affiliation":[{"name":"School of Clinical Methodology, IRCCS \u201cSacro Cuore-Don Calabria\u201d Hospital, 37024 Negrar di Valpolicella, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Joubert, N., Beck, A., Dumontet, C., and Denevault-Sabourin, C. (2020). Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals, 13.","DOI":"10.3390\/ph13090245"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: A look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","unstructured":"(2021, March 18). CPhI Annual Report 2018: ADCs Growth Driven by Lack of In-House Facilities, Oncology and Integrated CDMOs | Pharmaceutical Outsourcing\u2014The Journal of Pharmaceutical & Biopharmaceutical Contract Services. Available online: https:\/\/www.pharmoutsourcing.com\/Featured-Articles\/354437-CPhI-Annual-Report-2018-ADCs-Growth-Driven-by-Lack-of-In-House-Facilities-Oncology-and-Integrated-CDMOs\/."},{"key":"ref_6","unstructured":"(2021, March 18). Kadcyla, INN-Trastuzumab Emtansine Kadcyla-Epar-Product-Information_it.pdf. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kadcyla-epar-product-information_it.pdf."},{"key":"ref_7","unstructured":"(2020, February 27). Padcev SmPc.pdf, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761137s000lbl.pdf."},{"key":"ref_8","unstructured":"(2021, March 18). Enhertu-Epar-Product-Information_En.pdf. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enhertu-epar-product-information_en.pdf."},{"key":"ref_9","unstructured":"(2021, October 05). TRODELVY FDA, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761115s000lbl.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-Drug Conjugates in Cancer Therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"mAbs"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Corti, C., Giugliano, F., Nicol\u00f2, E., Ascione, L., and Curigliano, G. (2021). Antibody\u2013Drug Conjugates for the Treatment of Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13122898"},{"key":"ref_13","unstructured":"(2021, March 19). NCCN Guidelines Antiemesis, Version 2. Available online: https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf."},{"key":"ref_14","unstructured":"(2021, March 19). Linee Guida Aiom 2020 Terapia Antiemetica. Aiom. Available online: https:\/\/www.aiom.it\/linee-guida-aiom-2020-terapia-antiemetica\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO Guideline Update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab Emtansine with or without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results from the Phase III MARIANNE Study","volume":"35","author":"Perez","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"Huang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients with Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan","volume":"35","author":"Heist","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s00520-015-2750-5","article-title":"Impact and management of chemotherapy\/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists\/oncology nurses and patients: A cross-sectional multinational survey","volume":"23","author":"Vidall","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"McQuarrie, E.F., Stewart, D.W., and Shamdasani, P.N. (1990). Focus Groups: Theory and Practice, Sage Publications, Inc.","DOI":"10.2307\/3172875"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2013.08.049","article-title":"Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis","volume":"722","author":"Rojas","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","article-title":"Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy","volume":"94","author":"Vardy","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/annonc\/mdp584","article-title":"Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy","volume":"21","author":"Aapro","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00520-010-0941-7","article-title":"Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: A randomized, multicenter, phase III trial","volume":"19","author":"Celio","year":"2011","journal-title":"Support. Care Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00520-010-0980-0","article-title":"Anticipatory nausea and vomiting","volume":"19","author":"Roscoe","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/01635581.2018.1527375","article-title":"Randomized Study of the Effect of Dietary Counseling During Adjuvant Chemotherapy on Chemotherapy Induced Nausea and Vomiting, and Quality of Life in Patients with Breast Cancer","volume":"71","author":"Najafi","year":"2019","journal-title":"Nutr. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1517\/14740338.2013.830710","article-title":"Factors affecting patient\u2019s perception of anticancer treatments side-effects: An observational study","volume":"13","author":"Russo","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/107327481201902s03","article-title":"Patient-Centered Management of Chemotherapy-Induced Nausea and Vomiting","volume":"19","author":"Grunberg","year":"2012","journal-title":"Cancer Control"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/1022\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:21:41Z","timestamp":1760134901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/1022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14041022"],"URL":"https:\/\/doi.org\/10.3390\/cancers14041022","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]}}}